acarbose/orlistat (EMP16)
/ Empros Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
May 28, 2025
POEM: A Trial With EMP16 in Preparation for Late Phase Studies
(clinicaltrials.gov)
- P2 | N=39 | Not yet recruiting | Sponsor: Empros Pharma AB
New P2 trial • Genetic Disorders • Obesity
January 12, 2025
A Comparative Analysis of the Pharmacodynamic and Pharmacokinetic Properties of 2 Controlled-Release Formulations Versus a Marketed Orlistat Product.
(PubMed, Clin Pharmacol Drug Dev)
- "This shows that the new weight loss product MR-OA retains the dietary energy loss pathway used in Conv-O. Consistent with previous studies, minimal systemic absorption of orlistat and acarbose was observed for MR-OA, confirming that no significant alteration of the original substances occurs when modifying their release."
Journal • PK/PD data • Genetic Disorders
February 19, 2024
Study Exploring the Supportive Effect of Acarbose in Weight Management
(clinicaltrials.gov)
- P2 | N=320 | Active, not recruiting | Sponsor: Empros Pharma AB | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2023 ➔ Mar 2024
Enrollment closed • Trial completion date • Genetic Disorders • Obesity
October 04, 2023
A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: Empros Pharma AB | Not yet recruiting ➔ Recruiting
Enrollment open • Genetic Disorders • Obesity
August 28, 2023
A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=20 | Not yet recruiting | Sponsor: Empros Pharma AB
New P1 trial • Genetic Disorders • Obesity
July 06, 2023
Study Exploring the Supportive Effect of Acarbose in Weight Management
(clinicaltrials.gov)
- P2 | N=320 | Recruiting | Sponsor: Empros Pharma AB
New P2 trial • Genetic Disorders • Obesity • APOA1 • APOB
September 22, 2022
Effects of a novel weight-loss combination product containing orlistat and acarbose on obesity: A randomized, placebo-controlled trial.
(PubMed, Obesity (Silver Spring))
- "This trial indicates that orlistat and acarbose can be successfully combined in a modified-release formulation to provide efficacious weight loss with no unexpected safety issues. EMP16 may be a promising candidate among other medications for improved weight management."
Clinical • Journal • Genetic Disorders • Obesity
April 04, 2022
A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)
(clinicaltrials.gov)
- P2a | N=156 | Completed | Sponsor: Empros Pharma AB | Active, not recruiting ➔ Completed
Biomarker • Trial completion • Genetic Disorders • Obesity • CRP
August 20, 2021
A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)
(clinicaltrials.gov)
- P2a; N=156; Active, not recruiting; Sponsor: Empros Pharma AB; Recruiting ➔ Active, not recruiting; Trial completion date: Apr 2021 ➔ Aug 2021; Trial primary completion date: Apr 2021 ➔ Aug 2021
Biomarker • Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity • CRP
August 21, 2020
A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)
(clinicaltrials.gov)
- P2a; N=156; Recruiting; Sponsor: Empros Pharma AB
Biomarker • Clinical • New P2a trial • Genetic Disorders • Obesity
1 to 10
Of
10
Go to page
1